Looks like you’re on the UK site. Choose another location to see content specific to your location

Home Industry News Janssen combination therapy shows efficacy against multiple myeloma

Janssen combination therapy shows efficacy against multiple myeloma

8th June 2016

Janssen has announced new clinical trial results that demonstrate the benefits of a new daratumumab-based combination therapy for multiple myeloma.

Results from the phase III MMY3004 CASTOR clinical trial showed that daratumumab, when used in combination with bortezomib and dexamethasone, demonstrated a 61 percent progression-free survival improvement compared to bortezomib and dexamethasone alone.

The study involved patients with multiple myeloma who received a median of two prior lines of therapy, and it was also shown that the daratumumab-based regimen was associated with a significantly improved overall response rate.

Findings from the trial were presented at the American Society of Clinical Oncology's annual meeting in Chicago and will be used to support future regulatory submissions for this treatment approach.

Dr Peter Lebowitz, oncology therapeutic area head at Janssen Research and Development, said: "We look forward to presenting additional data on daratumumab at the Annual Congress of the European Hematology Association next week, which will expand our understanding of this promising compound in combination with standard therapies."

Daratumumab is currently approved conditionally in Europe as a monotherapy for adult patients with relapsed and refractory multiple myeloma. It is sold under the brand name Darzalex.ADNFCR-8000103-ID-801819889-ADNFCR

We currently have 6 jobs available in Pharmacy industry, find your perfect one now.

Stay informed

Receive the latest industry news, Tips
and straight to your inbox.